Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cardiovascular disease diagnostic agents - Kereos/Lantheus Medical Imaging

Next Previous
X
Search
Drug Profile

Research programme: cardiovascular disease diagnostic agents - Kereos/Lantheus Medical Imaging

Alternative Names: KI-0002

Latest Information Update: 04 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kereos
  • Developer Kereos; Lantheus Medical Imaging
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cardiovascular disorders

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cardiovascular-disorders(Diagnosis) in USA (Injection)
  • 31 May 2010 Preclinical development of KI 0002 as an MRI agent for use in the assessment of CVD is ongoing in the US
  • 08 Jan 2008 Bristol-Myers Squibb Medical Imaging has been acquired by Avista Capital Partners, and is now known as Lantheus Medical Imaging

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top